John M. Capek, Executive Vice President at ABBOTT LABORATORIES (ABT), sold 9,935 shares at $45.83 ($455K) on 2015-02-04, disclosed to the SEC on 2015-02-06.
Scheduled sale ($455k) by Executive Vice President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.82 | 3,900 | $179K | 39.2% |
| 2 | $45.83 | 100 | $5K | 1.0% |
| 3 | $45.83 | 800 | $37K | 8.1% |
| 4 | $45.83 | 1,935 | $89K | 19.5% |
| 5 | $45.84 | 100 | $5K | 1.0% |
| 6 | $45.84 | 200 |
| $9K |
| 2.0% |
| 7 | $45.85 | 2,200 | $101K | 22.2% |
| 8 | $45.85 | 300 | $14K | 3.0% |
| 9 | $45.86 | 400 | $18K | 4.0% |
| Total | $45.83 avg | 9,935 | $455K | 100% |
| Filing → |
| ABT | SELL | 2020-04-23 | $9.6M | — | Filing → |
| ABT | SELL | 2019-06-21 | $4.0M | — | Filing → |
| ABT | SELL | 2018-07-26 | $4.2M | — | Filing → |